Last Updated : May 12, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Perjeta-Herceptin Combo Pack | Pertuzumab-Trastuzumab Combo Pack | Early Breast Cancer | Do not reimburse | Complete | ||
| Osphena | ospemifene | Dyspareunia, vaginal dryness | Reimburse with clinical criteria and/or conditions | Complete | ||
| Imvexxy | estradiol | Dyspareunia | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xiaflex | Collagenase clostridium histolyticum | Dupuytren’s contracture | List with criteria/condition | Complete | ||
| Restasis ophthalmic emulsion | Cyclosporine | Dry eye disease | Do not list | Complete | ||
| Epidiolex | cannabidiol | Dravet Syndrome (DS) | Reimburse with clinical criteria and/or conditions | Active | ||
| Diacomit | Stiripentol | Dravet Syndrome | List with criteria/condition | Complete | ||
| Yescarta | axicabtagene ciloleucel | Diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Polivy | Polatuzumab Vedotin | Diffuse large B-cell lymphoma (DLBCL) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Minjuvi | tafasitamab | Diffuse large B-cell lymphoma (DLBCL) | Do not reimburse | Complete |
Last Updated : May 12, 2024